Verisk Analytics, Inc. (0LP3)
London Exchange · UK · prices in USD · close of 22 Oct 2026
Key indicators
| Last close | USD 202.65 |
|---|---|
| 52-week range | 154.94 – 239.29 |
| Return, 1 month / 3 months | +17.7% / +5.6% |
| Return, 1 year / 3 years | −14.2% / −11.7% |
| Trend | Uptrend |
| RSI (14) | 76 |
| Volatility (1 year) | 38.6% |
| Worst drawdown (1 year) | -33.9% |
| Average daily value traded | 0.09M USD |
| Dividend yield | 1.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Verisk Analytics is a data analytics company that serves insurers and other businesses with information and risk assessment tools. Its services include underwriting and claims data, catastrophe risk modelling, and fraud detection, drawn from large industry databases. Customers are mainly property and casualty insurers, along with healthcare, financial and government organisations. The company is based in Jersey City, New Jersey, in the United States, and operates internationally.
Verisk Analytics, Inc. trades under the code 0LP3 on the London Exchange in UK, with its price quoted in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Verisk Analytics, Inc. (0LP3) trades on the London Exchange in UK. It last closed at USD 202.65 on 22 October 2026.
Its price-based Market X-Ray is 47 out of 100 (a weak price profile), ranking 2,246 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 14.2% and over the last three months it rose 5.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 54 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 8.3% | ||
| From 52-week high | -15.1% | ||
| Momentum | 54 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 5.6% | ||
| 6-month return | 13.9% | ||
| 12-month return, skipping the last month | -27.1% | ||
| Stability (higher is calmer) | 42 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 38.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -33.9% | ||
| Liquidity | 29 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.09M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 50 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.0% | ||
| Years with dividends | 6 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +8.0% |
|---|---|
| 1 month | +17.7% |
| 3 months | +5.6% |
| 6 months | +13.9% |
| 1 year | −14.2% |
| 3 years | −11.7% |
| 5 years | −2.4% |
Signals
| 50-day / 200-day average | 179.75 / 187.08 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 7.37 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 Sep 2026 | USD 0.5000 |
| 15 Jun 2026 | USD 0.5000 |
| 13 Mar 2026 | USD 0.5000 |
| 15 Dec 2025 | USD 0.4500 |
| 15 Sep 2025 | USD 0.4500 |
| 13 Jun 2025 | USD 0.4500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.